For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.

多年来，基于血液的阿尔茨海默病生物标志物似乎无法实现，但最近的结果表明它们可能成为现实。新的高灵敏度分析产生的令人信服的数据已经出现，在不同的队列中具有显着的一致性，但也独立于所使用的精确分析方法。血液中淀粉样蛋白和磷酸化 tau 蛋白的浓度与脑脊液中的相应浓度以及淀粉样蛋白-PET 或 tau-PET 扫描相关。此外，其他基于血液的神经变性生物标志物，例如神经丝轻链和胶质纤维酸性蛋白，似乎可以提供有关疾病进展和监测治疗效果的潜力的信息。现在出现了一个问题，即我们何时以及如何将这些生物标志物用于临床实践。